



Patrick Roth

Contact

Patrick Roth

Publications (21)

Greselin M, Lu P, Melie-Garcia L, Ocampo-Pineda M, Galbusera R, Cagol A, Weigel M, de Oliveira Siebenborn N, Ruberte E, Benkert P, Müller S, Finkener S, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Diepers M, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravata E, Weber J, Gobbi C, Leppert D, Kim O, Cattin P, Hoepner R, Roth P, Kappos L, Kuhle J, Granziera C. Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort. *Bioengineering (Basel)* 2024; 11

Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. *BMC cancer* 2024; 24:82.

Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. *Neurooncol Pract* 2023; 11:132-141.

Hundsberger T, Schreiner B, Roth P. Immune checkpoint inhibitors induced side effects of the peripheral nervous system. *Curr Opin Neurol* 2023; 36:427-431.

Medici G, Freudenmann L, Velz J, Wang S, Kapoulou K, Paramasivam N, Mühlenbruch L, Kowalewski D, Vasella F, Bilich T, Frey B, Dubbelaar M, Patterson A, Zeitlberger A, Silgner M, Roth P, Weiss T, Wirsching H, Krayenbühl N, Bozinov O, Regli L, Rammensee H, Rushing E, Sahm F, Walz J, Weller M, Neidert M. A T-cell antigen atlas for meningioma: novel options for immunotherapy. *Acta Neuropathol* 2023; 146:173-190.

Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. *Invest New Drugs* 2023; 41:267-275.

Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Sellés Moreno C, Foëge M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. *Clin Cancer Res* 2022; 28:5368-5382.

Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). *Swiss Med Wkly* 2021; 151:w20501.

Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. *Clin Cancer Res* 2020; 27:179-188.

Roth P, Hofer S, Pesce G, Roelcke U, Mamot C, Reinert M, Schucht P, Läubli H, Hundsberger T, Hottinger A, Weller M. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. *Swiss Med Wkly* 2020; 150:w20256.

Wolpert F, Preusser M, Le Rhun E, Andratschke N, Neidert M, Roth P, Löb R, Lareida A, Grossebacher B, Berghoff A, Weller M. Venous thromboembolic events in patients with brain metastases: the PICOS score. *Eur J Cancer* 2020; 134:75-85.

Gramatzki D, Rogers J, Neidert M, Hertler C, Le Rhun E, Roth P, Weller M. Antidepressant drug use in glioblastoma patients: an epidemiological view. *Neurooncol Pract* 2020; 7:514-521.

Wolpert F, Le Rhun E, Imbach L, Poryazova R, Roth P, Neidert M, Grossenbacher B, Terziev R, Lareida A, Weller M. Risk factors for the development of epilepsy in patients with brain metastases. *Neuro Oncol* 2020; 22:718-728.

Zhu Y, Christiansen A, Fritz C, Rupp N, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild P, Aebersold R, Ljubicic J, Rutishauser D, Schmid M, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol Oncol* 2019; 13:2305-2328.

Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. *Eur J Cancer* 2018; 96:64-72.

Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. *Acta Neuropathol* 2018; 135:923-938.

Wick W, Golfopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). *Clin Cancer Res* 2016; 22:4797-4806.

Wolpert F, Weller M, Westphal M, Lamszus K, Neidert M, Roth P, Deenen R, Florea A, Reifenberger G, Happold C, Eisele G. Interferon- β Modulates the Innate Immune Response against Glioblastoma Initiating Cells. *PloS one* 2015; 10:e0139603.

Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. *Neurology* 2015; 84:1242-8.

Hundsberger T, Roth P, Roelke U. Neurologische Komplikationen bei onkologischen Patienten. *Praxis* 2014 2014; 103:1009-1016.

Hundsberger T, Roth P, Roelcke U. [Neurological complications in cancer patients]. *Praxis (Bern 1994)* 2014; 103:1009-16.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch